Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

In our exclusive interview, Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline.

Treatment approaches are being refined by the primary location of gastroesophageal junction tumors.

Treatment approaches are being refined by the primary location of gastroesophageal junction tumors.

Jean Wright, MD, discusses radiation considerations in breast cancer.

Jean Wright, MD, discusses radiation considerations in breast cancer.

Nivolumab, when administered approximately 4 weeks prior to surgery in patients with Merkel cell carcinoma, was found to be tolerable and to induce pathological complete responses and radiographic tumor regressions.

Jean Wright, MD, discusses proton versus photon radiotherapy in breast cancer.

Amanda Nickles Fader, MD, discusses the rationale for a phase II study and explains how the findings could open the door to other treatment options for women with uterine serous carcinoma.

Emmanuel S. Antonarakis, MBBCh, discusses the efficacy of radium-223 plus sipuleucel-T in patients with bone-metastatic castration-resistant prostate cancer and the next steps for research for this combination.

Amanda Nickles Fader, MD, discusses the utility of trastuzumab plus chemotherapy in HER2-positive uterine serous carcinoma.

Amanda Nickles Fader, MD, discusses the rationale for utilizing HER2/neu as a target in uterine serous carcinoma.

Tania Jain, MBBS, discusses the potential for graft-versus-host disease as a complication of allogeneic stem cell transplant.

Emmanuel S. Antonarakis, MBBCh, discusses the design of a randomized phase II study of sipuleucel-T with or without radium-223 dichloride in men with asymptomatic bone-metastatic castrate-resistant prostate cancer.

Tania Jain, MBBS, sheds light on the mutations that confer worse prognosis in myelofibrosis.

Benjamin P. Levy, MD, discusses emerging biomarkers and their respective therapies in lung cancer.

Tania Jain, MBBS, discusses treatment options for patients with myelofibrosis who progress following allogeneic stem cell transplant.

Emmanuel S. Antonarakis, MBBCh, discusses the utility of sipuleucel-T plus radium-223 in nonmetastatic castration-resistant prostate cancer.

Emmanuel S. Antonarakis, MBBCh, discusses the optimal use of PD-1/PD-L1 monotherapy in prostate cancer.

Tania Jain, MBBS, discusses blood count recovery in patients with hematology malignancies who receive CAR T-cell therapy.

Tania Jain, MBBS, discusses the role of allogeneic stem cell transplant in myelofibrosis.

Emmanuel S. Antonarakis, MBBCh, discusses updated data from the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Jean Wright, MD, discusses key strategies in using radiation therapy to treat patients with breast cancer.

Julie R. Brahmer, MD, discusses targeted treatments for patients with oncogene-driven non–small cell lung cancer.

Tania Jain, MBBS, discusses the challenges with allogeneic transplant in patients with myelofibrosis.

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.

Jean Wright, MD, discusses the evolution of radiation oncology in early-stage breast cancer and how novel radiation modalities are poised to transform the field.

Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses ongoing research regarding the use of liquid biopsies in lung cancer.

Benjamin P. Levy, MD, discusses the next steps with liquid biopsies in non–small cell lung cancer and its broader use in oncology.

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

Ramy Sedhom, MD, looks back on his first year of oncology fellowship and shares advice for first-year fellows and trainees.